-+ 0.00%
-+ 0.00%
-+ 0.00%

Acrivon Acquires JAK1 Inhibitor ACR-525, Preclinical Program From Aqilion

PUBT·11/06/2026 13:02:26
Listen to the news
Acrivon Acquires JAK1 Inhibitor ACR-525, Preclinical Program From Aqilion
  • Acrivon Therapeutics acquired Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKC theta inhibitor program from Aqilion.
  • The acquisition closed for undisclosed cash consideration, with no future royalty or milestone obligations.
  • The deal establishes immunology and inflammation as a strategic pillar alongside oncology.
  • Eosinophilic esophagitis is the first targeted indication for ACR-525, using a formulation designed for patients with difficulty swallowing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060800PRIMZONEFULLFEED9871989) on November 06, 2026, and is solely responsible for the information contained therein.